Supplementary materials: Cost–effectiveness and cost–benefit analysis of oliceridine in the treatment of acute pain
These are peer-reviewed supplementary tables for the article 'Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain' published in the Journal of Comparative Effectiveness Research.
- Supplementary Table 1. Estimated mean and median cost and length of stay (LOS) derived from the 2017 National Inpatient Sample-Healthcare Cost and Utilization Project (NIS-HCUP) dataset.
- Supplementary Table 2. Estimated cost weights for opioid-induced respiratory depression events by type of surgery (in 2017 US dollars).
- Supplementary Table 3. Health economic model cost weights for opioid-induced respiratory depression, vomiting, and somnolence inflated to 2020 US dollar costs.
- Supplementary Table 4. Base model estimates: Summary of impact of sensitivity analyses on the base model estimates.
- Supplementary Table 5. Oliceridine parameter values used in the Monte Carlo simulations (values for morphine parameters were similarly varied).
Summary: Aim: Oliceridine, a new class of μ-opioid receptor agonist, is selective for G-protein signaling (analgesia) with limited recruitment of β-arrestin (associated with adverse outcomes) and may provide a cost-effective alternative versus conventional opioid morphine for postoperative pain. Patients & methods: Using a decision tree with a 24-h time horizon, we calculated costs for medication and management of three most common adverse events (AEs; oxygen saturation <90%, vomiting and somnolence) following postoperative oliceridine or morphine use. Results: Using oliceridine, the cost for managing AEs was US$528,424 versus $852,429 for morphine, with a net cost savings of $324,005. Conclusion: Oliceridine has a favorable overall impact on the total cost of postoperative care compared with the use of the conventional opioid morphine.
